2012
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Research And Treatment 2012, 133: 1057-1065. PMID: 22418700, PMCID: PMC3387495, DOI: 10.1007/s10549-012-2003-y.Peer-Reviewed Original ResearchConceptsHER2-positive metastatic breast cancerErbB family blockerMetastatic breast cancerBreast cancer patientsAdverse eventsCancer patientsBreast cancerEastern Cooperative Oncology Group performance statusHER2-positive breast cancer patientsIrreversible ErbB family blockerMedian progression-free survivalTreatment-related adverse eventsPositive breast cancer patientsHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Common Terminology CriteriaMedian overall survivalObjective response ratePhase II studyProgression-free survivalGrowth factor receptor 2Single-arm studyPrior chemotherapy linesPromising clinical activityFactor receptor 2
2009
Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.
Hickish T, Wheatley D, Lin N, Carey L, Houston S, Mendelson D, Solca F, Uttenreuther-Fischer M, Jones H, Winer E. Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab. Cancer Research 2009, 69: 5060-5060. DOI: 10.1158/0008-5472.sabcs-09-5060.Peer-Reviewed Original ResearchHER2-positive metastatic breast cancerEpidermal growth factor receptorPhase II studyMetastatic breast cancerBIBW 2992Partial responseBreast cancerGrowth factor receptorII studyEastern Cooperative Oncology Group performance statusSingle-arm phase II studyHER2-positive breast cancer patientsTrastuzumab-resistant cell linesHER2-positive breast cancerHER2 tyrosine kinase inhibitorAdequate organ functionCutaneous adverse eventsEarly clinical responseObjective response rateFactor receptorBreast cancer patientsFailure of treatmentTyrosine kinase inhibitorsEligible patientsMeasurable diseaseUse of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab
Hickish T, Wheatley D, Lin N, Carey L, Houston S, Mendelson D, Solca F, Uttenreuther-Fischer M, Jones H, Winer E. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. Journal Of Clinical Oncology 2009, 27: 1023-1023. DOI: 10.1200/jco.2009.27.15_suppl.1023.Peer-Reviewed Original ResearchHER2-positive metastatic breast cancerPhase II studyMetastatic breast cancerBIBW 2992Tyrosine kinase inhibitorsPartial responseBreast cancerEpidermal growth factor receptorStable diseaseAdverse eventsII studyDisease progressionTumor assessmentOpen-label single-arm phase II studySide effectsEastern Cooperative Oncology Group performance statusSingle-arm phase II studyHER2-positive breast cancer patientsDual epidermal growth factor receptorArm phase II studyTrastuzumab-resistant cell linesEGFR/HER2 tyrosine kinase inhibitorHER2-positive breast cancerHER2 tyrosine kinase inhibitorAdequate organ function